Taking advantage of the intrinsic characteristics of NK/T cells, CD19 CAR-NK/T cells are able to target both CD19 and CD1d on MM cells, resulting in a reinforced anti-tumor effect as compared to CD19 CAR-T cells (10). This evidence concerns the gene CD1D and Miyoshi myopathy.